Department of Tuberculosis & Chest Diseases, 30036Sarojini Naidu Medical College, Agra.
Associate Professor, Department of Tuberculosis & Chest Diseases, 30036Sarojini Naidu Medical College, Agra.
Trop Doct. 2022 Jan;52(1):23-26. doi: 10.1177/00494755211050193. Epub 2021 Dec 6.
Tubercular empyema thoracis continues to be one of the leading causes of morbidity in low-income countries. Despite antitubercular therapy (ATT) and thoracostomy, empyema drainage is hampered by multiple septations, loculations, debris, and blood clots leading to complications. In a comparative experimental study to estimate the efficacy and safety of intrapleural streptokinase (IPSTK) in tubercular empyema, 30 cases of chronic multiloculated tubercular empyema were compared by radiological improvement by chest radiography, duration and volume of fluid drained, and degree of dyspnoea according to the modified Borg scale, depending on whether streptokinase was used or not. The former scored on all counts; we therefore conclude that intrapleural streptokinase is a safe, efficacious intervention in tubercular empyema. It decreases morbidity and reduces the need for surgery.
结核性脓胸仍然是低收入国家发病率的主要原因之一。尽管有抗结核治疗（ATT）和胸腔造口术，但由于多个分隔、包裹、碎片和血凝块导致引流困难，从而导致并发症。在一项比较性实验研究中，为了评估胸腔内链激酶（IPSTK）在结核性脓胸中的疗效和安全性，对 30 例慢性多房性结核性脓胸进行了比较，根据改良 Borg 量表，根据是否使用链激酶，通过胸部 X 射线改善、引流的持续时间和液体量以及呼吸困难程度来评估。前者在所有方面都得分；因此，我们得出结论，胸腔内链激酶是结核性脓胸的一种安全、有效的干预措施。它降低了发病率并减少了手术的需求。
